$108.50 0.5%
GILD Stock Price vs. AI Score
Data gathered: June 22

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Gilead Sciences (GILD)

Analysis generated March 11, 2025. Powered by Chat GPT.

Gilead Sciences, Inc. is an American biopharmaceutical company that focuses on the research, development, and commercialization of treatments for life-threatening diseases. Founded in 1987 and headquartered in Foster City, California, Gilead has grown into a prominent player in the biotechnology industry. The company’s portfolio includes treatments for HIV/AIDS, liver diseases, cancer, and inflammatory diseases. Gilead is known for its innovative approach to drug development, making it a key player in the healthcare sector.

Read full AI stock Analysis

Stock Alerts - Gilead Sciences (GILD)

company logo Gilead Sciences | June 19
Marjorie Taylor Greene (member of U.S. congress) is buying shares
company logo Gilead Sciences | June 18
Insider Alert: Mercier Johanna is selling shares
company logo Gilead Sciences | June 16
AI Score is up by 32.9% in the last couple of days.
company logo Gilead Sciences | June 15
AI Score is up by 32.1% in the last couple of days.

Download our app to get future alerts delivered in real-time.

About Gilead Sciences

Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.


Gilead Sciences
Price $108.50
Target Price Sign up
Volume 21,540,000
Market Cap $135B
Year Range $83.15 - $115.75
Dividend Yield 2.93%
PE Ratio 22.79
Analyst Rating 62% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '256.67B961M5.71B1.32B1.91B1.810
Q4 '247.57B1.58B5.99B1.78B3.11B1.900
Q3 '247.55B1.57B5.97B1.25B1.88B2.020
Q2 '246.95B1.54B5.41B1.61B2.98B2.010
Q1 '246.69B1.55B5.13B-4.17B-3.54B-1.320

Insider Transactions View All

Mercier Johanna filed to sell 120,168 shares at $110.2.
June 17 '25
Dickinson Andrew D filed to sell 165,110 shares at $110.2.
June 17 '25
O'Day Daniel Patrick filed to sell 620,268 shares at $111.
June 2 '25
O'Day Daniel Patrick filed to sell 623,852 shares at $110.1.
June 2 '25
Mercier Johanna filed to sell 121,152 shares at $107.5.
May 23 '25

Congress Trading View All

Politician Filing Date Type Size
Marjorie Taylor Greene
Jun 19, 25 Buy $1K - $15K
Josh Gottheimer
Jun 12, 25 Sell $1K - $15K
Marjorie Taylor Greene
May 7, 25 Buy $1K - $15K

What is the Market Cap of Gilead Sciences?

The Market Cap of Gilead Sciences is $135B.

What is Gilead Sciences' PE Ratio?

As of today, Gilead Sciences' PE (Price to Earnings) ratio is 22.79.

What is the current stock price of Gilead Sciences?

Currently, the price of one share of Gilead Sciences stock is $108.50.

How can I analyze the GILD stock price chart for investment decisions?

The GILD stock price chart above provides a comprehensive visual representation of Gilead Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gilead Sciences shares. Our platform offers an up-to-date GILD stock price chart, along with technical data analysis and alternative data insights.

Does GILD offer dividends to its shareholders?

Yes, Gilead Sciences (GILD) offers dividends to its shareholders, with a dividend yield of 2.93%. This dividend yield represents Gilead Sciences' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Gilead Sciences in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.

What are some of the similar stocks of Gilead Sciences?

Some of the similar stocks of Gilead Sciences are Amgen, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Chat with AltIndex AI

👋 Welcome to AltIndex AI Chat!

Ask about:
  • Top Stocks
  • AI score insights
  • Trending investment opportunities
  • How to use AltIndex
You need to log in to use AltIndex AI Chat.
Disclaimer: AI outputs may be incorrect. This is for informational purposes only and not a substitute for professional financial advice.